Management Team

Julie Cherrington, Ph.D.

President and CEO

Dr. Julie M. Cherrington, Ph.D. is a life science executive with extensive experience bringing drugs into the clinic and through to commercialization. She has been a key contributor to the successful development of multiple FDA approved products, including SUTENT™, Palladia™, Vistide™, Viread™, and Hepsera™.

Julie currently serves as President and CEO of Arch Oncology, an immuno-oncology company. Most recently, Julie served as President and CEO of Revitope, also an immune-oncology company and before that was President and CEO of Zenith Epigenetics, a bromodomain inhibitor company. From 2009 to 2014, Julie was President and CEO of Pathway Therapeutics, a clinical stage company advancing targeted kinase inhibitors. Prior to joining Pathway, she served as President and EVP of R&D of Phenomix Corporation. Prior to joining Phenomix in 2003, Julie was vice president of preclinical and clinical research at SUGEN, a Pharmacia/Pfizer company. Julie began her career at Gilead Sciences where she held a range of positions of increasing responsibility.

She has served on the Boards of Directors of Chemgenex, Progen and Xenome. She is currently a member of the Scientific Advisory Board of the Clearity Foundation and is an advisor in entrepreneurship initiatives at the California Life Sciences Institute (CLSI), UC San Francisco, and UC Davis.

Daniel Pereira, PhD

Chief Scientific Officer

Dr. Dan Pereira brings to Arch Oncology more than 20 years of experience as a scientist, project leader, manager and strategist in the biotech and pharmaceutical industries. He and his teams have contributed to the research and development of ~100 biologic drug candidates for oncology that include mono/bispecific antibodies, ADCs and Immuno-oncology candidates. Of these, currently four oncology therapeutics have gained regulatory approval – Erbitux, Cyramza, Portrazza and Lartruvo.

Prior to joining Arch Oncology, Dr. Pereira was VP, Discovery Research at Agensys Inc., an affiliate of Astellas Pharmaceuticals Inc. (2011-2017); Site Head and VP, Research at Roche/Arius, Hoffmann-La Roche Limited (2006-2010); and Director Tumor Biology at ImClone Systems, Inc. (1998-2006).

Dr. Pereira received his doctorate training with Dr. Frank Graham at McMaster University and his post-doctoral training with Dr. John Dick at the University of Toronto.

Vicki Sung, Ph.D.

Vice President of Translational Medicine

Dr. Sung currently serves as Vice President of Translational Medicine at Arch Oncology. She has nearly 20 years of oncology drug development experience spanning across the pipeline from target discovery and validation through pharmacology and late stage clinical development. Dr. Sung spent the past 10 years leading translational efforts for hematology and oncology programs at Celgene San Francisco (formerly Pharmion), where she participated in the advancement of drugs from IND through phase 3 clinical trials. Prior to Celgene, Dr. Sung held R&D positions at Novartis/Chiron and Sugen/ Pharmacia/Pfizer, where she contributed to the validation and development of both small molecules and biologics.

Dr. Sung received her Ph.D. in Cell Biology from Georgetown University School of Medicine, completed postdoctoral studies in Endocrinology at Stanford University School of Medicine and holds M.S. and B.S. degrees from Georgetown University and UC Berkeley, respectively.

William A. Frazier, Ph.D.


Dr. Frazier is a professor of Biochemistry, Molecular Biophysics, and Cell Biology at Washington University School of Medicine. He discovered that CD47 is a receptor for thrombospondin-1. Having contributed to over 140 publications, Dr. Frazier has been a leader in the field of CD47-mediated signaling pathways for many years. He founded the company in 2006 based on research from his laboratory and that of his collaborators at the National Institutes of Health. Dr. Frazier holds a B.A. from Johns Hopkins University and a Ph.D. from Washington University in St. Louis.

Pamela T. Manning, Ph.D.


Dr. Manning co-founded the company in 2006 and served as Vice President of Research until 2018. Her broad expertise in pharmacology spans multiple therapeutic areas including neuroscience, cardiovascular, oncology, inflammation and pain. She is also internationally recognized in the field of nitric oxide research. Dr. Manning received her Ph.D. in Pharmacology from the Ohio State University, completed postdoctoral studies in pharmacology at Washington University School of Medicine and holds an M.S. and B.S. from Wright State University.